Mission Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer. The company holds and aims to maintain world-leadership in DNA repair and associated molecular mechanisms, particularly those involving enzymes of the ubiquitin pathway. Mission Therapeutics will use its knowledge and proven expertise in targeting these pathways for small-molecule drug discovery to develop new therapeutic agents with wide market potential. These drugs mainly target “Achilles heels” of diseased tissues by exploiting the concept of synthetic-lethality.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.